SREBP1 upregulates the expression of the glutamine transporter ASCT2, and pharmacological targeting of ASCT2 or glutaminase, in combination with pimozide, disrupts this cycle, inducing significant mitochondrial damage and oxidative stress, leading to GBM cell death both in vitro and in vivo [108]. The gene discussed is SLC1A5; the disease is glioblastoma.